GE HealthCare TechnologiesMEX:GEHC 63 Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus rates MEX:GEHC with a GF Score™ of 63/100 and a GF Value™ of MXN1,488.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, GE HealthCare Technologies ranks better than 99.87% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. GE HealthCare Technologies's annualized net income for the quarter that ended in Mar. 2026 was MXN28,059 Mil. GE HealthCare Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN-94,975 Mil. Therefore, GE HealthCare Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was Negative Tangible Equity%.
The historical rank and industry rank for GE HealthCare Technologies's Return-on-Tangible-Equity or its related term are showing as below:
MEX:GEHC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 141.68 Med: 622.04 Max: 1102.39
Current: Negative Tangible Equity
During the past 7 years, GE HealthCare Technologies's highest Return-on-Tangible-Equity was 1,102.39%. The lowest was 141.68%. And the median was 622.04%.
MEX:GEHC's Return-on-Tangible-Equity is ranked better than 99.87% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs MEX:GEHC: Negative Tangible Equity
GE HealthCare Technologies (MEX:GEHC) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
GE HealthCare Technologies Return-on-Tangible-Equity Related Terms
GE HealthCare Technologies Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GE HealthCare Technologies Return-on-Tangible-Equity Chart
MEX:GEHC vs DXCM, STE, ZBH: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, GE HealthCare Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GE HealthCare Technologies Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where GE HealthCare Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
GE HealthCare Technologies (MEX:GEHC) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on GE HealthCare Technologies and its competitors. Over the past decade, GE HealthCare Technologies' Return-on-Tangible-Equity has ranged from 141.68 to 1,102.39. According to the industry distribution chart, GE HealthCare Technologies ranks #1 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is GE HealthCare Technologies' Return-on-Tangible-Equity too high?
GE HealthCare Technologies' current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 141.68 to a high of 1,102.39. Based on the distribution chart, GE HealthCare Technologies ranks #1 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, GE HealthCare Technologies has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' Return-on-Tangible-Equity compare to DXCM and STE?
According to the Medical Devices & Instruments industry distribution chart, GE HealthCare Technologies ranks #1 out of 759 companies for Return-on-Tangible-Equity. This places GE HealthCare Technologies in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.07. Historically, GE HealthCare Technologies' own Return-on-Tangible-Equity has ranged from 141.68 to 1,102.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on GE HealthCare Technologies and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GE HealthCare Technologies's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (MEX:GEHC) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,488.78, compared to a current price of MXN1,149.89 — trading 22.8% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. GE HealthCare Technologies' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For GE HealthCare Technologies (MEX:GEHC), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GE HealthCare Technologies (MEX:GEHC) Overvalued in 2026?
Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued.
The current stock price of MXN1,149.89 is trading 22.8% below its estimated GF Value™ of MXN1,488.78.
GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.
No single metric tells the full story. See the MEX:GEHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
63GF Score
Get the complete analysis for MEX:GEHC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GEHC has been successfully added to your 
